Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Estradiol Valerate

FDA-approved product (injectable, injection), marketed as Delestrogen, Estradiol Valerate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Estradiol Valerate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrophic Vaginitis
  • Atrophy
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Dyspareunia
  • Hypogonadism
  • Menopause
  • Menorrhagia
  • Osteoporosis
  • Postmenopausal atrophic vaginitis
  • Postmenopausal osteoporosis
  • Premature ovarian insufficiency
  • Primary ovarian insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural and semisynthetic estrogens, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Estradiol Valerate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estradiol Valerate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

    NCT07766369 · start 2026-08-12

    Registered record
    Registry ID
    NCT07766369
    Conditions
    Healthy Volunteers
    Interventions
    E2086
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-12
    Completion
    2026-11-12
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionE2086
    PhasePhase 1
    Registry statusNot yet recruiting

  • Association Between Female Hormonal Profile and Wound Healing

    NCT07724145 · start 2026-07

    Registered record
    Registry ID
    NCT07724145
    Conditions
    Wound Healing; Wound Healing Complication; Estradiol
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2028-12
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWound Healing; Wound Healing Complication; Estradiol
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer

    NCT05982496 · start 2026-06-09

    Registered record
    Registry ID
    NCT05982496
    Conditions
    Breast Cancer Female; Lobular Breast Carcinoma; PET/MRI; Axillary Lymphadenopathy; Luminal A Breast Cancer
    Interventions
    FES; PET/MRI A; Translational analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-09
    Completion
    2029-12-01
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female; Lobular Breast Carcinoma; PET/MRI; Axillary Lymphadenopathy +1 more
    InterventionFES; PET/MRI A; Translational analysis
    PhasePhase 2
    Registry statusRecruiting

  • Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause

    NCT06873971 · start 2025-12-10

    Registered record
    Registry ID
    NCT06873971
    Conditions
    Genitourinary Syndrome of Menopause
    Interventions
    Topical estrogen therapy based on estriol (E3); Active Er:YAG Laser; Sham Er:YAG laser (minimal fluence)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-12-10
    Completion
    2026-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGenitourinary Syndrome of Menopause
    InterventionTopical estrogen therapy based on estriol (E3); Active Er:YAG Laser; Sham Er:YAG laser (minimal fluence)
    PhaseNot applicable
    Registry statusRecruiting

  • Estrogen Variability and Irritability During the Menopause Transition

    NCT05388656 · start 2022-06-15

    Registered record
    Registry ID
    NCT05388656
    Conditions
    Menopause; Irritable Mood
    Interventions
    Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release; Placebo; Progesterone 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-06-15
    Completion
    2025-01-17
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Irritable Mood
    InterventionEstradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release; Placebo; Progesterone 200 mg
    PhasePhase 4
    Registry statusCompleted

  • CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

    NCT05251714 · start 2022-05-27

    Registered record
    Registry ID
    NCT05251714
    Conditions
    Advanced Solid Tumor; Breast Cancer
    Interventions
    CFI-402257; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-05-27
    Completion
    2026-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Breast Cancer
    InterventionCFI-402257; Fulvestrant
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

    NCT05362760 · start 2022-04-27

    Registered record
    Registry ID
    NCT05362760
    Conditions
    Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer
    Interventions
    Abemaciclib + Aromatase Inhibitor; Abemaciclib + Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-04-27
    Completion
    2029-04
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer
    InterventionAbemaciclib + Aromatase Inhibitor; Abemaciclib + Fulvestrant
    PhasePhase 4
    Registry statusRecruiting

  • China Gender-affirming Hormone Therapy Study

    NCT05318755 · start 2022-04-16

    Registered record
    Registry ID
    NCT05318755
    Conditions
    Transgender; Gender Incongruence
    Interventions
    GAHT for transgender men; GAHT for transgender women
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-04-16
    Completion
    2028-12-31
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransgender; Gender Incongruence
    InterventionGAHT for transgender men; GAHT for transgender women
    PhaseNot recorded
    Registry statusRecruiting

  • A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

    NCT07739589 · start 2021-10-25

    Registered record
    Registry ID
    NCT07739589
    Conditions
    Residual Drug Amount of EE and LNG
    Interventions
    Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-10-25
    Completion
    2021-11-16
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResidual Drug Amount of EE and LNG
    InterventionTwirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
    PhasePhase 4
    Registry statusCompleted

  • A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

    NCT05064332 · start 2021-10-08

    Registered record
    Registry ID
    NCT05064332
    Conditions
    Healthy
    Interventions
    PF-06650833; Ethinyl estradiol (EE) and levonogestrel (LN)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-08
    Completion
    2021-12-16
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-06650833; Ethinyl estradiol (EE) and levonogestrel (LN)
    PhasePhase 1
    Registry statusCompleted

  • Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

    NCT04841499 · start 2021-04-05

    Registered record
    Registry ID
    NCT04841499
    Conditions
    Menopause
    Interventions
    BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-04-05
    Completion
    2021-07-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause
    InterventionBASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
    PhaseNot applicable
    Registry statusCompleted

  • Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

    NCT04112368 · start 2020-09-15

    Registered record
    Registry ID
    NCT04112368
    Conditions
    Suicidal Ideation
    Interventions
    Estradiol Transdermal Patch 0.1 mg/24 hrs; Oral Micronized Progesterone 200mg; Inactive Clear Patch; Placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-09-15
    Completion
    2024-08-01
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuicidal Ideation
    InterventionEstradiol Transdermal Patch 0.1 mg/24 hrs; Oral Micronized Progesterone 200mg; Inactive Clear Patch; Placebo capsule
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Estrogen-intrauterine Stent System After Intrauterine Adhesiolysis

    NCT04972032 · start 2020-09-02

    Registered record
    Registry ID
    NCT04972032
    Conditions
    Intrauterine Adhesion
    Interventions
    Estrogen Intrauterine Stent System; Foley balloon combined with self-cross-link sodium hyaluronate gel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-09-02
    Completion
    2025-03
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrauterine Adhesion
    InterventionEstrogen Intrauterine Stent System; Foley balloon combined with self-cross-link sodium hyaluronate gel
    PhaseNot applicable
    Registry statusUnknown

  • A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

    NCT05418426 · start 2020-08-18

    Registered record
    Registry ID
    NCT05418426
    Conditions
    Vulvovaginal Atrophy; Vasomotor Symptoms
    Interventions
    IVR Dose 1; IVR Dose 2; Oral Reference
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-08-18
    Completion
    2022-01-27
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginal Atrophy; Vasomotor Symptoms
    InterventionIVR Dose 1; IVR Dose 2; Oral Reference
    PhasePhase 1
    Registry statusCompleted

  • The Effect of the GM-CSF Gel on the Endometrial Thickness in Infertile Women With Thin Endometrium

    NCT04100655 · start 2019-10

    Registered record
    Registry ID
    NCT04100655
    Conditions
    Thin Endometrium
    Interventions
    GM-CSF; 17-ß estradiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-10
    Completion
    2020-12
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThin Endometrium
    InterventionGM-CSF; 17-ß estradiol
    PhaseNot applicable
    Registry statusUnknown